JDRF, PureTech Try Nonprofit Ownership To Fill Funding Gap For Diabetes Tech
This article was originally published in The Gray Sheet
Executive Summary
Call it venture philanthropy with a twist: If all goes as planned, the Juvenile Diabetes Research Foundation will co-own a series of companies dedicated to type 1 diabetes treatments without violating tax code, thanks to a structure created by Boston’s PureTech Ventures.
You may also be interested in...
Enlight: Pharmas Collaborate on Novel Start-up
Merck, Lilly and Pfizer team up with PureTech Ventures to form Enlight Biosciences, a novel start-up developing next-generation technologies that promise to speed the way drugs are found and developed.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.